Expanding Treatment Options for Metastatic Prostate Cancer
Year: 2011
Type: editorial
Abstract: Prostate cancer is an androgen-receptor–dependent disease, and the blocking of androgen-receptor signaling is a hallmark of prostate-cancer therapeutics. Although most patients initially benefit from therapy involving deprivation of gonadal androgen, the disease eventually progresses after 12 to 48 months, depending on the disease burden, host factors, and inherent tumor biology. After progression, the disease evolves into a new clinically and molecularly heterogeneous state known as castration-resistant prostate cancer, which is invariably fatal.The clinical course of metastatic castration-resistant prostate cancer has changed considerably, primarily because of factors such as earlier diagnosis, stage migration, and changes in practice patterns. Earlier initiation . . .
Source: New England Journal of Medicine
DOI: 10.1056/nejme1102758
Institution: Sidney Kimmel Comprehensive Cancer Center
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: green
Funder: National Cancer Institute
Award: SPORE in Prostate Cancer
OpenAlex ID: W2036311277
